Lilly Not So Nuts to Cling to Solanezumab?
Results of the two phase 3 trials of Lilly’s solanezumab and the two phase 3 trials of Pfizer/JNJ’s bapineuzumab in mild-moderate Alzheimer disease have...
Read More
-
About Pathophilia
Lilly’s Compound Shows Marginal Benefit in Mild Alzheimer Disease
Solanezumab, Lilly’s anti-amyloid MAb, may provide some clinical benefit in patients with mild AD, according to data presented yesterday by the AD Cooperative...
Read More
For Alzheimer’s, Amyloid Hypothesis Remains Viable; But Bapineuzumab Is Probably Dead
The unequivocally negative clinical results of the phase 3 studies of bapineuzumab do little to promote or detract from the idea that accumulating amyloid in the brain...
Read More
Lilly’s AD Compound: Perhaps Not Dead Yet
Lilly effectively made a small cup of lemonade out of 2 big lemons on Friday, when the company released its expected, negative phase 3 results of solanezumab in...
Read More
Pfizer/Janssen Kill Bapi Development for Alzheimer’s
Aaaand, it’s over. Yesterday (after the bell), Pfizer and Janssen announced the discontinuation of their development program for IV bapineuzumab, the anti-amyloid...
Read More
Bapineuzumab Disappoints in 1st of 4 Late-Phase Alzheimer Trials
In a development that isn’t terribly surprising, Pfizer released disappointing data yesterday evening from its (and Janssen’s) phase 3 study of the...
Read More